Figure 5.

NF-κB is required for PRRSV-induced IL-1β production. (a, b) PAMs were mock infected or infected with PRSSV at a MOI of 0.1, followed by treatment with NF-κB inhibitor (1, 2, 5, 10, and 20 μM) or DMSO vehicle in the absence of serum, for 36 h. The cells and supernatants were then harvested separately and analyzed by real-time RT-PCR (a) and ELISA (b), respectively. *P < 0.05 and **P < 0.01 compared with DMSO-treated cells plus PRRSV infection.